Navigation Links
Kinase test may yield big gains for drug-resistant cancers
Date:4/12/2012

Chapel Hill, NC In a paper published today in the journal Cell, a team from the University of North Carolina at Chapel Hill unveils the first broad-based test for activation of protein kinases "en masse", enabling measurement of the mechanism behind drug-resistant cancer and rational prediction of successful combination therapies.

Kinases are proteins expressed in human tissues that play a key role in cell growth, particularly in cancer. Of the 518 known human kinases, about 400 are expressed in cancers, but which ones and how many are actually active in tumors has been difficult to measure. Tremendous efforts have been made to develop kinase inhibitors as cancer treatments, which have resulted in key drugs such as Herceptin, Tykerb, and Gleevec. However, in spite of the effectiveness of this class of cancer drugs, most cancers eventually become resistant. The UNC team has developed a test that can measure both the presence and activity of 60-70 percent of all kinases simultaneously, allowing investigators to see how cancers evade treatment with kinase inhibitors so that they can combine drugs to block resistance.

Gary Johnson, PhD, the project's principal investigator, says, "Single-agent kinase inhibitors are promising in principle, but often fail in practice because the network of tumor kinases learns how to get around the inhibitor, leading to rapid drug resistance. We're very excited about the test our lab has developed because it works very well in a model of breast cancer to predict the success of combination therapies."

Johnson, who is the Kenan Distinguished Professor and chair of the department of pharmacology in the UNC School of Medicine and a member of UNC Lineberger Comprehensive Cancer Center, is working with UNC Breast Center medical director Lisa Carey, MD, UNC Lineberger director Shelley Earp, MD, and surgical oncologist Keith Amos, MD, to perform clinical trials using the technology with the goal of real-time, personalized therapies for breast cancer.

"One of the most frustrating things as an oncologist is when a patient's tumor develops resistance to a treatment," says Carey, who is also a member of UNC Lineberger. "We are excited about the ability to examine tumor samples before, during, and after kinase inhibitor treatment to see how the tumor kinase profile changes, and potentially respond to those changes using different inhibitors."

The team hopes to be able to track and define the kinase 'reprogramming' that takes place in tumors during therapy and to use the new test to identify combinations of drugs that will block the cancer's adaptive behavior that leads to drug resistance. A patent application has been filed for the testing technology.


'/>"/>
Contact: Ellen de Graffenreid
edegraff@med.unc.edu
919-962-3405
University of North Carolina School of Medicine
Source:Eurekalert

Related medicine news :

1. Battlefield camaraderie yields long-term dividends for veterans, study finds
2. Why do physicians order costly CTs? Ultrasound yields better diagnosis, safer, less costly
3. Gene Sequencing Yields Picture of Human Gut
4. HealthSouth To Present at Barclays Capital 2010 High Yield Bond and Syndicated Loan Conference
5. Abbreviated Trials Yield Misleading Results: Study
6. H1N1 Virus Yields Up More Secrets
7. Safety and diagnosis yield of colonoscopy in Hong Kong Chinese children
8. Glued graft for Pterygium Yield Better Cosmetic Results
9. Pigs Yield Clues to Cystic Fibrosis-Related Lung Disease
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. In infant heart surgery, newer technique yields better survival in first year of life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... ... America Walks , a national advocacy organization that promotes walking and ... Pittsburgh Graduate School of Public Health , has been awarded a Walking College ... around the country to participate in a four-month training program designed to strengthen local ...
(Date:5/25/2016)... ... May 25, 2016 , ... "FCPX LUT Intense allows ... your footage," said Christina Austin - CEO of Pixel Film Studios. , With ... and easily add stylish color grades to their footage. A LUT is a Lookup ...
(Date:5/25/2016)... ... May 25, 2016 , ... Consumer access to organic foods and grower access ... maker of whole grain cereals and other plant-based foods, will introduce the first consumer ... winter wheat processed by Hesco/Dakota Organic Products. , The transitional designation means the cereal ...
(Date:5/25/2016)... ... 25, 2016 , ... Stern Environmental Group , of Secaucus, New Jersey, ... as Stern’s Real Time Monitoring (RTM) Device. Stern Environmental Group will sell ... industry, colleges for use in dormitories, shelters, and nursing homes for real time bedbug ...
(Date:5/24/2016)... ... 2016 , ... Sterling Global Products is launching a Kickstarter campaign focused on ... dispenser. The campaign kick-off video is located via this link https://youtu.be/WsO4qz2odco . The ... is to raise $1,000 per day for a total of $25,000. The funds will ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... , May 23, 2016 The World Health Organization ... device to include adolescents aged 13 years, and above. ... be offered for adult and adolescent males in the 14 ... . PrePex was the first male circumcision device to receive ... CEO, Eddy Horowitz said: " The expanded ...
(Date:5/23/2016)... 2016 Gamida Cell, a leader ... cancer and orphan genetic diseases, announced today it has ... from the Israel Innovation Authority (formerly the Office of ... and Industry. The mission of the Israel Innovation Authority ... including science and technology, while stimulating economic growth. ...
(Date:5/22/2016)... , May 23, 2016 ... develop its anti-fibrotic and anti-inflammatory compound DS102 in ... as in non-alcoholic steatohepatitis (NASH) patients. ... significantly sequestered in lung tissue and has bronchodilatory, ... after oral administration. The Company will publish further ...
Breaking Medicine Technology: